An open, parallel trial to study the effect of hepatic impairment on eluxadoline pharmacokinetics

Trial Profile

An open, parallel trial to study the effect of hepatic impairment on eluxadoline pharmacokinetics

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Eluxadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacokinetics
  • Sponsors Furiex Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2017 Results published in the Journal of Clinical Pharmacology
    • 20 Apr 2016 New trial record
    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top